vs
Ginkgo Bioworks Holdings, Inc.（DNA）与Ponce Financial Group, Inc.（PDLB）财务数据对比。点击上方公司名可切换其他公司
Ginkgo Bioworks Holdings, Inc.的季度营收约是Ponce Financial Group, Inc.的1.1倍（$33.4M vs $31.4M），Ponce Financial Group, Inc.同比增速更快（37.6% vs -23.8%），Ponce Financial Group, Inc.自由现金流更多（$54.6M vs $-47.7M），过去两年Ponce Financial Group, Inc.的营收复合增速更高（23.7% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
庞塞金融集团是总部位于美国的金融控股公司，核心子公司为庞塞银行，主要服务纽约大都会区的多元文化、移民及中低收入社区，提供存款账户、按揭贷款、小微企业融资、个人信贷等零售及商业银行服务。
DNA vs PDLB — 直观对比
营收规模更大
DNA
是对方的1.1倍
$31.4M
营收增速更快
PDLB
高出61.4%
-23.8%
自由现金流更多
PDLB
多$102.3M
$-47.7M
两年增速更快
PDLB
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $31.4M |
| 净利润 | — | $10.1M |
| 毛利率 | — | — |
| 营业利润率 | -211.9% | 43.6% |
| 净利率 | — | 36.3% |
| 营收同比 | -23.8% | 37.6% |
| 净利润同比 | — | 245.6% |
| 每股收益（稀释后） | $-1.41 | $0.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNAPDLB
| Q4 25 | $33.4M | $31.4M | ||
| Q3 25 | $38.8M | $26.7M | ||
| Q2 25 | $49.6M | $26.5M | ||
| Q1 25 | $48.3M | $24.6M | ||
| Q4 24 | $43.8M | $22.8M | ||
| Q3 24 | $89.0M | $20.2M | ||
| Q2 24 | $56.2M | $20.2M | ||
| Q1 24 | $37.9M | $20.5M |
净利润DNAPDLB
| Q4 25 | — | $10.1M | ||
| Q3 25 | $-80.8M | $6.5M | ||
| Q2 25 | $-60.3M | $6.1M | ||
| Q1 25 | $-91.0M | $6.0M | ||
| Q4 24 | — | $2.9M | ||
| Q3 24 | $-56.4M | $2.4M | ||
| Q2 24 | $-217.2M | $3.2M | ||
| Q1 24 | $-165.9M | $2.4M |
营业利润率DNAPDLB
| Q4 25 | -211.9% | 43.6% | ||
| Q3 25 | -231.8% | 32.8% | ||
| Q2 25 | -132.1% | 30.2% | ||
| Q1 25 | -184.1% | 32.5% | ||
| Q4 24 | -236.3% | 19.6% | ||
| Q3 24 | -62.0% | 15.2% | ||
| Q2 24 | -396.7% | 21.8% | ||
| Q1 24 | -469.1% | 18.3% |
净利率DNAPDLB
| Q4 25 | — | 36.3% | ||
| Q3 25 | -207.9% | 24.3% | ||
| Q2 25 | -121.6% | 23.0% | ||
| Q1 25 | -188.2% | 24.2% | ||
| Q4 24 | — | 14.1% | ||
| Q3 24 | -63.3% | 12.1% | ||
| Q2 24 | -386.4% | 15.8% | ||
| Q1 24 | -437.3% | 11.8% |
每股收益（稀释后）DNAPDLB
| Q4 25 | $-1.41 | $0.43 | ||
| Q3 25 | $-1.45 | $0.27 | ||
| Q2 25 | $-1.10 | $0.25 | ||
| Q1 25 | $-1.68 | $0.25 | ||
| Q4 24 | $-1.91 | $0.11 | ||
| Q3 24 | $-1.08 | $0.10 | ||
| Q2 24 | $-4.23 | $0.14 | ||
| Q1 24 | $-3.32 | $0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | $126.2M |
| 总债务越低越好 | — | $596.1M |
| 股东权益账面价值 | $508.6M | $541.5M |
| 总资产 | $1.1B | $3.2B |
| 负债/权益比越低杠杆越低 | — | 1.10× |
8季度趋势，按日历期对齐
现金及短期投资DNAPDLB
| Q4 25 | $422.6M | $126.2M | ||
| Q3 25 | $495.5M | $146.6M | ||
| Q2 25 | $559.4M | $126.6M | ||
| Q1 25 | $325.3M | $129.9M | ||
| Q4 24 | $561.6M | $139.8M | ||
| Q3 24 | $616.2M | $155.8M | ||
| Q2 24 | $730.4M | $103.2M | ||
| Q1 24 | $840.4M | $134.7M |
总债务DNAPDLB
| Q4 25 | — | $596.1M | ||
| Q3 25 | — | $521.1M | ||
| Q2 25 | — | $536.1M | ||
| Q1 25 | — | $521.1M | ||
| Q4 24 | — | $596.1M | ||
| Q3 24 | — | $580.4M | ||
| Q2 24 | — | $680.4M | ||
| Q1 24 | — | $680.4M |
股东权益DNAPDLB
| Q4 25 | $508.6M | $541.5M | ||
| Q3 25 | $559.8M | $529.8M | ||
| Q2 25 | $613.0M | $521.1M | ||
| Q1 25 | $647.4M | $513.9M | ||
| Q4 24 | $716.1M | $505.5M | ||
| Q3 24 | $797.9M | $504.6M | ||
| Q2 24 | $833.1M | $497.7M | ||
| Q1 24 | $987.3M | $493.7M |
总资产DNAPDLB
| Q4 25 | $1.1B | $3.2B | ||
| Q3 25 | $1.2B | $3.2B | ||
| Q2 25 | $1.2B | $3.2B | ||
| Q1 25 | $1.3B | $3.1B | ||
| Q4 24 | $1.4B | $3.0B | ||
| Q3 24 | $1.5B | $3.0B | ||
| Q2 24 | $1.6B | $2.8B | ||
| Q1 24 | $1.6B | $2.8B |
负债/权益比DNAPDLB
| Q4 25 | — | 1.10× | ||
| Q3 25 | — | 0.98× | ||
| Q2 25 | — | 1.03× | ||
| Q1 25 | — | 1.01× | ||
| Q4 24 | — | 1.18× | ||
| Q3 24 | — | 1.15× | ||
| Q2 24 | — | 1.37× | ||
| Q1 24 | — | 1.38× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $55.6M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $54.6M |
| 自由现金流率自由现金流/营收 | -142.8% | 173.9% |
| 资本支出强度资本支出/营收 | 0.0% | 3.1% |
| 现金转化率经营现金流/净利润 | — | 5.48× |
| 过去12个月自由现金流最近4个季度 | — | $74.3M |
8季度趋势，按日历期对齐
经营现金流DNAPDLB
| Q4 25 | $-47.7M | $55.6M | ||
| Q3 25 | $-31.6M | $1.4M | ||
| Q2 25 | $-40.3M | $6.2M | ||
| Q1 25 | $-51.5M | $13.1M | ||
| Q4 24 | $-42.4M | $7.2M | ||
| Q3 24 | $-103.5M | $-14.6M | ||
| Q2 24 | $-84.4M | $-2.6M | ||
| Q1 24 | $-89.3M | $1.5M |
自由现金流DNAPDLB
| Q4 25 | $-47.7M | $54.6M | ||
| Q3 25 | — | $786.0K | ||
| Q2 25 | $-40.3M | $5.9M | ||
| Q1 25 | $-59.1M | $12.9M | ||
| Q4 24 | $-56.1M | $4.5M | ||
| Q3 24 | $-118.6M | $-15.0M | ||
| Q2 24 | $-111.4M | $-2.6M | ||
| Q1 24 | $-96.0M | $-315.0K |
自由现金流率DNAPDLB
| Q4 25 | -142.8% | 173.9% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | -81.2% | 22.4% | ||
| Q1 25 | -122.4% | 52.6% | ||
| Q4 24 | -128.0% | 19.7% | ||
| Q3 24 | -133.2% | -74.1% | ||
| Q2 24 | -198.2% | -13.0% | ||
| Q1 24 | -252.9% | -1.5% |
资本支出强度DNAPDLB
| Q4 25 | 0.0% | 3.1% | ||
| Q3 25 | 0.0% | 2.3% | ||
| Q2 25 | 0.1% | 1.0% | ||
| Q1 25 | 15.8% | 0.6% | ||
| Q4 24 | 31.3% | 11.9% | ||
| Q3 24 | 16.9% | 2.0% | ||
| Q2 24 | 48.1% | 0.3% | ||
| Q1 24 | 17.7% | 8.7% |
现金转化率DNAPDLB
| Q4 25 | — | 5.48× | ||
| Q3 25 | — | 0.21× | ||
| Q2 25 | — | 1.01× | ||
| Q1 25 | — | 2.20× | ||
| Q4 24 | — | 2.46× | ||
| Q3 24 | — | -5.99× | ||
| Q2 24 | — | -0.80× | ||
| Q1 24 | — | 0.61× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
PDLB
暂无分部数据
